Wed, Dec 17, 2014, 10:16 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

MetroPCS Communications, Inc. Message Board

bocamp1 178 posts  |  Last Activity: 12 hours ago Member since: Oct 13, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The investigator has informed us that he has submitted an abstract for the ASH annual meeting in December 2014 in which he has analyzed certain safety and efficacy data from MF patients in the MF Pilot Study and updated his analysis from the preliminary data he presented in December 2013. In accordance with ASH policies, abstracts submitted to the ASH annual meeting are embargoed from the time of submission. To be eligible for presentation at the ASH annual meeting, information contained in the abstract, as well as additional data and information to be presented at the annual meeting, may not be made public before the abstract has been published/presented in connection with the ASH annual meeting. We have not reviewed or independently analyzed the data selected by the investigator for inclusion in the abstract. Our analyses may result in conclusions that are materially different from the investigator's analyses and therefore additional or updated data should be considered carefully and with caution. Please refer to the risk factor entitled, "Risks Related to Our Business-Success in early clinical trials may not be indicative of results in subsequent clinical trials. Likewise, data reported by investigators from time-to-time is subject to review and verification procedures that could result in material differences to final data and may change as more patient data becomes available." in Part II, Item 1A entitled, "Risk Factors", in this Form 10-Q.

  • Reply to

    Results in abstract

    by rusty_98070 Nov 6, 2014 9:07 AM
    bocamp1 bocamp1 Nov 6, 2014 9:13 AM Flag

    This is very good results; CR's and PR's. There is no drug that does this. And spleen reduction. But a short cabal has control of stock, just like the Washington Post said the other day about small bio's.
    Shorts just look at the understated conclusion and naked short, with their deep pockets. But, science will rule the day and anything under 2 1/2 is a good buy

  • bocamp1 by bocamp1 Sep 29, 2014 9:10 PM Flag

    Filed today for a transaction done on 9/26/14. The form appears to show an open market purchase of 125,000 shares at .19. This gives him almost 500k shares.
    If this were an open market purchase it would be super bullish but total volume for that day was only 55,000 shares, so that would be impossible. The last form 4 by Beecher was filed in correctly(as it appears this one is) as an open market purchase also.
    I can give vaso's legal team a pass on incorrectly filing the first form 4 a while back, but the fact that they continue to file incorrectly can only lead one to believe that they are purposely trying to deceive investors and shareholders here.
    This is IMHO a 4 related to stock grant but 4 does not show that. Vaso's lawyer is our buddy Leiberman, who has been paid handsomely over the years in company stock. Does he not understand what form he should file and what info should be on form????????????????
    Can this friggin company do anything right?

  • bocamp1 by bocamp1 Oct 7, 2014 11:53 AM Flag

    Its nice to see, but dont know if it has legs. Stock is very oversold
    We need some positive news. Company has been silent as even IR doesn't respond.

  • DTD 9/28/14. The Post doesn't do fluff pieces. They have clout and if enough pressure is put on politicians the worm will turn very quickly. There is no way the naked short position here can be covered without a huge price spike. You can google whole article

    The Post article explains how hedge funds can manipulate and actually control the stock prices of small biotechnology companies through short selling strategies. Short sales are done by borrowing shares from another party that owns the shares. These shares can be sold in the market without the seller ever owning them. The short seller must at some time in the future purchase the shares. While short selling is perfectly legal, some short sellers simply don’t bother to borrow the shares. This is naked short selling and it is illegal according to the Washington Post. This can result in overwhelming price pressure on a stock by an unending stream of naked short sells.

    Integral to the naked short selling is the operation of dark pools by brokerage firms. It is widely alleged by small biotech companies and their investors that dark pools don’t enforce the requirement for a short seller to deliver borrowed stock within three days of shorting. It is alleged that hedge funds can create an unlimited supply of stock through naked shorting. The compliance officers of the brokerage firm have turned a blind eye to this practice. This could change. The Attorney General of New York is already investigating dark pools for high frequency trading. He can easily expand the investigation to see if they are involved in naked shorting.

    The hedge funds use very complex trading strategies that involve trading in dark pools, high frequency trading and sophisticated put and call strategies. They use this technique to walk a stock down. In this technique, a group of hedge funds conspire to systematically take out all bids for stocks for days on end with short selling Less

    . .

  • Reply to

    Dr. Ma - how is MY money in good hands today...?

    by cstauss7 Nov 28, 2014 11:43 AM
    bocamp1 bocamp1 Nov 28, 2014 4:52 PM Flag

    From the many CC I have listened to and after attending the shareholder meeting, its clear that Ma either doesn't understand the questions in English and his subsequent answers; or he is a liar. There can be no other explanation. The problem for shareholders is that in either case, he is a terrible CEO and a destroyer of our equity.

  • Reply to

    MobiCare/Ebola

    by bocamp1 Oct 12, 2014 7:10 PM
    bocamp1 bocamp1 Oct 13, 2014 10:04 AM Flag

    SIMH sells 100 Thermometers and is up almost 200%. We need an update on MobiCare as it relates to Ebola and units sold. Lets go Ma.

  • bocamp1 by bocamp1 Oct 12, 2014 7:10 PM Flag

    Can Vaso be the next Ebola play? Does MobiCare really have value here, as statement below by company seems to indicate? The market is looking for anything in this space; lake and apt, and smaller unknowns like simh and psid all are rallying on even the smallest possibility.
    There is no doubt since the latest report of a healthcare worker in the USA contacting Ebola, that caregiver exposure must be kept to a minimum.
    We shall see.............................

    "We appreciate the opportunity to work with the Bangpakok Hospital Group to explore various applications of our products. In addition to providing remote viewing capabilities of monitoring a patient’s vital signs, thereby enabling consultation from a distant location, the MobiCare system also presents as a great ally in the battle against highly contagious diseases, such as Ebola, by minimizing exposure to only necessary physical contact between the patient and care staff."

  • bocamp1 by bocamp1 Nov 5, 2014 1:11 PM Flag

    All medical device makers higher today as device tax might get cut or eliminated with election results. Vaso has said in the past this has cut into "profits." But, as usual no response here.
    Earnings date announced today. Ma has promised in SEC documents that we will have actual earnings this Q. Everyone should hold him to it. No more excuses. Ma's pay package should be cut to better align with shareholder returns if he has lied.
    What you say, Ma? More of your mumbo jumbo nonsense at CC? Lets hope not.

  • What is his relationship with the Chinese Government? And Ma? Why did vaso value the company Genwell at 2.1 million. He is part owner and an employee of Vaso. He and his wife also received 190,000 dollars from the original Chinese acquisition.
    We bought LET 3 years ago to vertically integrate EECP. But, THERE NEVER has been any demand for eecp. Why would we need to pay for manufacturing end of eecp when there has never been the "increased demand" Ma spoke about at the time of the acquisition. This all looks like Chinese Checkers to shareholders.
    Ma needs to be held accountable for wasting all our money on his Chinese buddies.

  • bocamp1 bocamp1 Dec 4, 2014 8:00 PM Flag

    Mia, must you start your lovers quarrel all over again. Take it somewhere else.

  • Reply to

    You guys are to much.

    by corkedwine Dec 10, 2014 1:39 PM
    bocamp1 bocamp1 Dec 10, 2014 8:26 PM Flag

    Corked, I am against any Chinese, Black, Hispanic, Indian,or Caucasian CEO who runs a company I OWN into the ground (as defined by share price decline), lies about it, and increases his pay substantially doing same. Now, you may be more forgiving than I, or you may believe in Ma's personal practice of wealth redistribution, or you just may be plain stupid; I don't know. To defend this strategy after 3 years of failure, I think the latter.
    But how about this since we will never agree , lets meet at the next shareholder meeting, and you can call me racist and I will call you stupid and we will see what happens.
    And, in the interim, why don't you do a little reading on the increasing nationalism in China as it applies to our corporation doing business there. How they steal IP and force our companies to submit to competitive practices well outside of the WTO. That left leaning paper NY Times has many good articles about this which, hopefully, wont offend your progressive sensibilities.

  • Shareholders deserve a statement from the CEO.

  • The analyst estimates that peak U.S. sales for Cynapsus’s thin film strip apomorphine product, APL-130277, will be about $300-million. Applying the same multiple that Acorda paid for Citivias, which was 1.05 sales, implies a $315-million takeout, or $2.18 per share, points out Pearlstein. He expects this might happen in six to eight months, after the results of CTH-300a, double-blind, placebo-controlled, parallel-design study with Parkinson’s patients who have at least one “off” episode every 24 hours, with total “off” time of at least 2 hours, are made available.

    In a research update to clients Friday, Pearlstein maintained his “Buy” rating and $1.75 one-year target on Cynapsus Therapeutics, implying a return of 182% at the time of publication

  • bocamp1 by bocamp1 Sep 30, 2014 12:12 PM Flag

    This form by Beecher was done as a grant and was listed as such in the transaction code section. It has been my experience that most of these forms would make a verbal explanation under the "remarks section"; but vaso does not chose to do this. But, my mistake. No buy but a "properly coded" grant.
    Party on vaso. Free stock for everyone(but us shareholders.

  • bocamp1 by bocamp1 Oct 13, 2014 3:25 PM Flag

    Market getting crushed again and scln closing near highs? This is not the normal scln action, and I have been in and out of stock for years. Some real news coming very soon. Ebola related ?

  • Reply to

    MobiCare/Ebola

    by bocamp1 Oct 12, 2014 7:10 PM
    bocamp1 bocamp1 Oct 13, 2014 9:25 AM Flag

    Companies are getting huge market cap gains for just the smallest demand for a device that they can put out a pr saying order was Ebola related.
    Just take a look at SIMH this morning. They sold a grand total of 100 thermometers last week and stock is up 70% this morning. So, it would not take many orders for Mobi to get this stock moving big. Of course, a properly worded PR by vaso would be needed to get this started.

  • DTD 9/28/14. The Post doesn't do fluff pieces. They have clout and if enough pressure is put on politicians the worm will turn very quickly. There is no way the naked short position here can be covered without a huge price spike. You can google whole article

    The Post article explains how hedge funds can manipulate and actually control the stock prices of small biotechnology companies through short selling strategies. Short sales are done by borrowing shares from another party that owns the shares. These shares can be sold in the market without the seller ever owning them. The short seller must at some time in the future purchase the shares. While short selling is perfectly legal, some short sellers simply don’t bother to borrow the shares. This is naked short selling and it is illegal according to the Washington Post. This can result in overwhelming price pressure on a stock by an unending stream of naked short sells.

    Integral to the naked short selling is the operation of dark pools by brokerage firms. It is widely alleged by small biotech companies and their investors that dark pools don’t enforce the requirement for a short seller to deliver borrowed stock within three days of shorting. It is alleged that hedge funds can create an unlimited supply of stock through naked shorting. The compliance officers of the brokerage firm have turned a blind eye to this practice. This could change. The Attorney General of New York is already investigating dark pools for high frequency trading. He can easily expand the investigation to see if they are involved in naked shorting.

    The hedge funds use very complex trading strategies that involve trading in dark pools, high frequency trading and sophisticated put and call strategies. They use this technique to walk a stock down. In this technique, a group of hedge funds conspire to systematically take out all bids for stocks for days on end with short selling

  • Reply to

    dump finkel

    by snogreen Oct 24, 2014 6:52 PM
    bocamp1 bocamp1 Oct 24, 2014 7:54 PM Flag

    One thing we know about SNO, he/she never relents. It doesn't matter right or wrong he will push his bias ad nauseam. When he was fighting with Mia, he played the ultimate jilted lover.
    So, he is now hell bent on rehashing the past in regard to Fink, when he knows Fink is going nowhere. This is classic Sno. He has now articulated his reason for not buying rgrx. Its Fink.
    Sno will never buy rgrx, and Fink has little to do with it. But, it will now become his more aggressive storyline as to why RGRX will never make it. And when he is proven wrong again, as he was with scln, he/she will quietly disappear; off to play the disgruntled "bullish" investor somewhere else.
    Sno is a tool; an instrument of a greater short cabal. As the gains here get more real, he will have to post much more often, and it will be just more of the same. Sno is a loser hoping to steal potential gains from all potential investors; just ask any who ignored his warnings on scln and were richly rewarded.
    The only history that matters here now is Sno's. And that guide tells us to stay very long as shareholders are about to hit another winner. We should all thank him for his consistency; the ultimate contrarian indicator.

  • Is he connected with the Chinese government? Is he related to Ma or anyone else at company? None of the SEC docs give his name; why?
    He and vp of BIOX just got almost 2.1 million dollars from us shareholders. They both work for Vaso. Chinese government determined what we shareholders paid. Was this really an arms length transaction? Sounds like a cherry deal for a company whose only assets are patents and IP.
    Is this deal accretive also? Maybe in Ma's World it is.

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.